Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 3014

Next Previous
Drug Profile

GEN 3014

Alternative Names: GEN-3014; HexaBody®-CD38

Latest Information Update: 17 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Complement activation stimulants; Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 10 Mar 2025 Johnson & Johnson decides to not exercise its option to receive a worldwide license to develop, manufacture and commercialize GEN 3014
  • 10 Mar 2025 Discontinued - Phase-I/II for Haematological malignancies (Second-line therapy or greater) in Ukraine, Philippines, Macedonia, New Zealand, Moldova, Malaysia, South Korea, Hungary, Georgia, Czech Republic, Bosnia-Herzegovina, Greece, France, Spain, Poland, Netherlands, Australia, USA, Sweden, Denmark (IV)
  • 10 Mar 2025 Efficacy and adverse events data from a phase I/II trial in Hematological malignancy released by Genmab

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top